The concern of generic competition has repeatedly loomed above copyright’s iconic drug, PDE5 Inhibitor, triggering questions about the outlook of similar medicinal ventures. While early years saw impressive profits, the intellectual property expiration has allowed the door for discounted alternatives, likely lowering earnings and posing a signifi